- Home
- CRBU vs DBI Comparison
CRBU vs DBI Comparison
Compare CRBU & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- DBI
- Stock Information
- Founded
- CRBU 2011
- DBI 1991
- Country
- CRBU United States
- DBI United States
- Employees
- CRBU N/A
- DBI N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- DBI Clothing/Shoe/Accessory Stores
- Sector
- CRBU Health Care
- DBI Consumer Discretionary
- Exchange
- CRBU Nasdaq
- DBI Nasdaq
- Market Cap
- CRBU 188.8M
- DBI 161.1M
- IPO Year
- CRBU 2021
- DBI 1991
- Fundamental
- Price
- CRBU $1.90
- DBI $2.88
- Analyst Decision
- CRBU Strong Buy
- DBI Hold
- Analyst Count
- CRBU 4
- DBI 2
- Target Price
- CRBU $8.50
- DBI $3.50
- AVG Volume (30 Days)
- CRBU 1.8M
- DBI 1.1M
- Earning Date
- CRBU 08-12-2025
- DBI 09-10-2025
- Dividend Yield
- CRBU N/A
- DBI 6.97%
- EPS Growth
- CRBU N/A
- DBI N/A
- EPS
- CRBU N/A
- DBI N/A
- Revenue
- CRBU $9,918,000.00
- DBI $2,949,575,000.00
- Revenue This Year
- CRBU $9.52
- DBI N/A
- Revenue Next Year
- CRBU N/A
- DBI $2.45
- P/E Ratio
- CRBU N/A
- DBI N/A
- Revenue Growth
- CRBU N/A
- DBI N/A
- 52 Week Low
- CRBU $0.66
- DBI $2.18
- 52 Week High
- CRBU $3.00
- DBI $8.19
- Technical
- Relative Strength Index (RSI)
- CRBU 53.41
- DBI 48.07
- Support Level
- CRBU $1.86
- DBI $2.55
- Resistance Level
- CRBU $2.13
- DBI $2.92
- Average True Range (ATR)
- CRBU 0.22
- DBI 0.21
- MACD
- CRBU -0.05
- DBI -0.04
- Stochastic Oscillator
- CRBU 15.76
- DBI 33.85
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.